Boehringer Ingelheim's experimental drug afatinib obtained priority-review status from the FDA as a treatment for locally advanced or metastatic nonsmall-cell lung cancer in patients with epidermal growth factor receptor mutations. A decision is expected by the third quarter.
FDA expedites review of Boehringer's lung cancer drug afatinib
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||